Switzerland - German - Swissmedic (Swiss Agency for Therapeutic Products)

amavita health care ag - acidum acetylsalicylicum - tabletten - säure acetylsalicylicum 500 mg, excipiens pro compresso. - analgeticum, antipyreticum - synthetika

Switzerland - German - Swissmedic (Swiss Agency for Therapeutic Products)

coop vitality health care gmbh - acidum acetylsalicylicum - tabletten - säure acetylsalicylicum 500 mg, excipiens pro compresso. - analgeticum, antipyreticum - synthetika

Switzerland - German - Swissmedic (Swiss Agency for Therapeutic Products)

bayer (schweiz) ag - acidum acetylsalicylicum - brausetabletten - säure acetylsalicylicum 324 mg, saccharinum natricum, conserv.: e 211, excipiens pro compresso. - analgetikum, antipyretikum - synthetika

Switzerland - German - Swissmedic (Swiss Agency for Therapeutic Products)

hänseler ag - acidum acetylsalicylicum - tabletten - carbasalatum calcicum 528 mg endwerte. säure acetylsalicylicum 415 mg, excipiens pro compresso. - analgetikum, antipyretikum - synthetika

European Union - German - EMA (European Medicines Agency)

acino ag - clopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antithrombotische mittel - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , , , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease, non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa), st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy, patients suffering from acute coronary syndrome. , ,.

European Union - German - EMA (European Medicines Agency)

viatris limited - clopidogrel besilate - peripheral vascular diseases; stroke; myocardial infarction - antithrombotische mittel - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st-segment elevation acute myocardial infarction, in kombination mit ass bei medizinisch behandelten patienten, für die eine thrombolytische therapie. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. weitere informationen finden sie in abschnitt 5.

European Union - German - EMA (European Medicines Agency)

taw pharma (ireland) limited - clopidogrel-hydrochlorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antithrombotische mittel - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

European Union - German - EMA (European Medicines Agency)

sanofi winthrop industrie - clopidogrel-hydrogensulfat - stroke; peripheral vascular diseases; atrial fibrillation; myocardial infarction; acute coronary syndrome - antithrombotische mittel - secondary prevention of atherothrombotic eventsclopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from seven days until less than six months) or established peripheral arterial disease;adult patients suffering from acute coronary syndrome:non-st-segment-elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa);st-segment-elevation acute myocardial infarction, in combination with asa in patients undergoing percutaneous coronary intervention (including patients undergoing a stent replacement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy. in patients with moderate to high-risk transient ischemic attack (tia) or minor ischemic stroke (is)clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event. prävention von atherothrombotischen und thromboembolischer ereignisse bei vorhofflimmern fibrillationin erwachsenen patienten mit vorhofflimmern, die mindestens einen risikofaktor für vaskuläre ereignisse, sind nicht geeignet für die behandlung mit vitamin-k-antagonisten und haben ein geringes blutungsrisiko, clopidogrel ist indiziert in kombination mit ass für die prävention von atherothrombotischen und thromboembolischer ereignisse, einschließlich schlaganfall.

European Union - German - EMA (European Medicines Agency)

bayer ag - rivaroxaban - arthroplasty, replacement; venous thromboembolism - antithrombotische mittel - xarelto, co-verabreicht mit acetylsalicylsäure (asa) allein oder mit ass plus clopidogrel oder ticlopidine, ist indiziert für die prävention von atherothrombotischen ereignissen bei erwachsenen patienten nach einem akuten koronarsyndrom (acs) mit erhöhten kardialen biomarkern. xarelto, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. prävention venöser thromboembolien (vte) bei erwachsenen patienten, die sich einer hüft- oder kniegelenksersatzoperation unterziehen. behandlung von tiefen venenthrombosen (tvt) und lungenembolie (pe) und prävention von wiederkehrenden dvt und pe bei erwachsenen. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Austria - German - AGES (Agentur für Gesundheit und Ernährungssicherheit)

g.l. pharma gmbh - acetylsalicylsÄure; ascorbinsÄure - acetylsalicylsäure, kom